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Abstract
 
In spontaneous inflammatory arthritis of K/BxN T cell receptor transgenic mice, the effector
phase of the disease is provoked by binding of immunoglobulins (Igs) to joint surfaces. Inflamma-
tory cytokines are known to be involved in human inflammatory arthritis, in particular rheu-
matoid arthritis, although, overall, the pathogenetic mechanisms of the human affliction remain
unclear. To explore the analogy between the K/BxN model and human patients, we assessed
the role and relative importance of inflammatory cytokines in K/BxN joint inflammation by
transferring arthritogenic serum into a panel of genetically deficient recipients. Interleukin (IL)-1
proved absolutely necessary. Tumor necrosis factor (TNF)–
 

 
 was also required, although
seemingly less critically than IL-1, because a proportion of TNF-
 

 
–deficient mice developed
robust disease. There was no evidence for an important role for IL-6. Bone destruction and re-
construction were also examined. We found that all mice with strong inflammation exhibited
the bone erosion and reconstruction phenomena typical of K/BxN arthritis, with no evidence
of any particular requirement for TNF
 

 
 for bone destruction. The variability in the require-
ment for TNF-
 

 
, reminiscent of that observed in treated rheumatoid arthritis patients, did not
appear genetically programmed but related instead to subtle environmental changes.
Key words: transgenic • cytokine • knockout • inflammatory • TNF
 
Introduction
 
Inflammatory arthritides, in particular rheumatoid arthritis,
have been the focus of intense investigation, but their etiol-
ogy and pathogenesis remain controversial. There is no
consensus on what initiates rheumatoid arthritis (RA)
 
*
 
; i.e.,
whether it is primarily an autoimmune response, an in-
flammatory response to some persisting microbial invasion,
or a combination of the two. There is also dispute over the
leukocyte populations that are involved in the initiation of
joint inflammation. The paradigm currently dominating
the field portrays antigen-specific T cells in the joint as in-
citing the inflammatory cascade by triggering macrophages
and synoviocytes (1, 2), but this scenario has been ques-
tioned for a lack of direct experimental demonstration of
certain of its key points, and because of some discordant
observations, such as the paucity of T cell–derived cyto-
kines in inflamed joints (3). In contrast, a role for inflamma-
tory cytokines like TNF-
 

 
 and IL-1 is well established (4),
most demonstratively by the impressive effect of therapeu-
tic protocols that block TNF–TNF-R interactions (1).
There has also been debate on the relative importance of
the IL-1 and TNF-
 

 
 pathways (4). It has also been noted
that, even in the best of trial outcomes, arthritis is not fully
reversed and roughly one third of RA patients are refrac-
tory to TNF–TNFR-blocking drugs.
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Inflammatory Cytokines in K/BxN Arthritis
 
The K/BxN TCR transgenic mouse is a recently devel-
oped model of inflammatory arthritis (5–9). All K/BxN an-
imals spontaneously show an autoimmune disease with
most (although not all) of the clinical, histological, and im-
munological features of RA in humans. The disorder is
critically dependent on both T and B cells. Although the
pathologic manifestations are joint-specific, the process is
initiated, and then perpetuated, by dual T/B cell autoreac-
tivity to a ubiquitously expressed antigen, glucose-6-phos-
phate isomerase (GPI). Transfer of anti-GPI Igs from ar-
thritic K/BxN mice into healthy animals provokes arthritis
within days, even when the recipients are devoid of lym-
phocytes. GPI–anti-GPI immune complexes (Ics) are the
link between the systemic T and B lymphocyte autoreac-
tivity and the ensuing joint-specific inflammation and de-
struction; the joint specificity is perhaps a reflection of the
presence of GPI on the articular cavity surface (10). Initia-
tion of the inflammatory effector phase requires both the
complement network and Fc receptors (11). The relevance
of the K/BxN model to human RA is supported by a re-
cent report that serum from almost two thirds of RA pa-
tients contained anti-GPI Abs, absent from serum of nor-
mal individuals or of patients with Lyme arthritis or
Sjogren’s syndrome (12), although more recent data show
less obvious a correlation (unpublished data). The observa-
tion of GPI and GPI–anti-GPI complexes on cartilage sur-
faces of human joints is also of interest (10).
Our early studies on K/BxN mice revealed augmented
local synthesis of inflammatory cytokines, such as IL-6 and
TNF-
 

 
, in arthritic joints (5). However, the functional rel-
evance of this observation was not tested, other than a re-
port that failed to demonstrate a required role for TNF-
 

 
(13). The role of inflammatory cytokines is an important
element to consider in attempting to relate the mechanisti-
cally defined mouse model to human RA patients. For ex-
ample, does Ig-induced arthritis correspond to the TNF
 

 
-
dependent form of the human disease or rather to the
variants resistant to TNF
 

 
/TNFR blockade?
Here, we apply the K/BxN serum transfer system to a
panel of mice deficient in one or more inflammatory cyto-
kines or their receptors. A critical role for IL-1 is estab-
lished, along with a strong, but not absolute, requirement
for TNF
 

 
. Interestingly, we find that the requirement for
TNF
 

 
 varies markedly from individual to individual, as it
does in humans.
 
Materials and Methods
 
Mice.
 
The knockout mice used for serum transfer were ob-
tained from the Jackson Laboratory, brought to our animal facility
at the Harvard Medical School animals facility at 4–5 wk of age,
and used 1–3 wk later (in rare exceptions, the mice were bred in
our colony). These mice include the following: IL-6
 

 
/
 

 
 (14) on
a B6 background; IL-1r1
 

 
/
 

 
 on both B6 (15) and (B6 
 

 
 129)F2
(16) backgrounds; TNF
 

 
/
 

 
 (17) on a (B6 
 

 
 129)F2 back-
ground; Lta
 

 
/
 

 
 on the (B6 
 

 
 129)F2 background (18);
TNFR1
 

 
/
 

 
 (19) and TNFR2
 

 
/
 

 
 (20) on a B6 background;
and TNFR1/2
 

 
/
 

 
 (21) on a (B6 
 

 
 129)F2 background.
 
RNA Analysis.
 
RNA was prepared from ankle tissue by a
modification of the LiCl/urea technique (22), designed to avoid
contamination of the joint RNA with bone marrow–derived ma-
terial by leaving the bone intact. After dissection of ankles (sec-
tioned at the long bones of the lower leg and in the metatarsal
area), the tissue was freed of skin and superficial tendons. The
joint was immersed in 1 ml RNA solubilization solution (6 M
urea, 2% SDS). Articular cavities were opened with a scalpel and
were exposed to the medium to release the cellular contents. Af-
ter 10-min incubation, the fragment was removed, and an equal
volume of concentrated LiCl solution (6 M LiCl, 6 M urea, and
10 mM sodium acetate, pH 5) was added to precipitate the
RNA. cDNA was synthesized from these RNAs by MuLV re-
verse transcriptase (GIBCO BRL).
Cyclophilin was used as an endogenous control using a probe
concentration of 200 and 400 nM for each primer in each reac-
tion. The probe and primers sequences used are as follows: probe,
5
 

 
 VIC CTTGGGCCGCGTCTCCTT TAMRA 3
 

 
; forward
primer, 5
 

 
 CAGACGCCACTGTCGCTTT 3
 

 
; and reverse
primer, 5
 

 
 TGTCTTTGGAACTTTGTCTGCAA 3
 

 
. For the
quantification of TNF
 

 
 and IL6, the TaqMan predeveloped assay
reagents were used (PE, Applied Biosytems). For IL1 
 

 
, the
probe and primer concentrations per reaction were the same as
those used for cyclophilin. The probe and primers sequences used
are as follows: probe, 5
 

 
 FAM TGCAGCTGGAGAGTGTG-
GATCCCA TAMRA 3
 

 
; forward primer, 5
 

 
 TGAAAGACG-
GCACACCCA 3
 

 
; and reverse primer, 5
 

 
 AAACCGCTTTTC-
CATCTTCTTCT 3
 

 
. To determine relative expression values,
 

 
C
 
T
 
 (C
 
T
 
 cytokine 
 
 
 
C
 
T
 
 cyclophilin) was used to derive an ex-
pression index (2
 

 
CT
 
), which was then divided by the same index
obtained with a reference sample of total spleen RNA.
 
Serum Transfer Protocol and Arthritis Scoring.
 
K/BxN serum
pools were prepared from arthritic mice 60 d old. Arthritis was
induced by intraperitoneal injection of 150–200 
 

 
l serum at days
0 and 2. A clinical index was evaluated over time (1 point for
each affected paw; 0.5 points for a paw with only mild swelling/
redness or only a few digits affected). Ankle thickness was mea-
sured by a caliper (6), with ankle thickening being defined as the
difference in ankle thickness from the day 0 measure.
 
Histology.
 
Hind limbs were collected and the knee and ankle
joints were separated mid-tibia. Specimens were dissected to re-
move skin and outer muscle, and subsequently fixed in 4%
paraformaldehyde for a minimum of 12 h and demineralized for
 

 
2 wk in 14% EDTA, followed by paraffin embedding (model
Citadel 1000; Shandon). For each specimen, twenty 4-
 

 
m sagit-
tal serial sections were cut, and every fifth section was stained
with hematoxylin and eosin (Sigma-Aldrich) for evaluation of in-
flammation, bone erosion, and cartilage destruction. An adjacent
section was stained with toluidine blue (Sigma-Aldrich) for spe-
cific evaluation of proteoglycan. Histopathological scoring was
performed as described previously (5, 23).
 
Results and Discussion
 
Kinetics of Inflammatory Cytokine Production.
 
Transfer of
K/BxN serum into normal recipients induces rapid and
synchronous development of arthritis, the first signs of joint
inflammation appearing within 24 h in fully susceptible
strains (9). To begin exploring the induction of various in-
flammatory cytokines in this model and their temporal re-
lationships, we measured the expression of their mRNAs
by quantitative real-time PCR. C57Bl/6 mice were in-
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jected with a single dose of K/BxN serum, RNA was pre-
pared at different times thereafter from ankle tissue (pooled
from two individuals), and real-time PCR was performed
to quantitate spliced TNF-
 

 
, IL-1
 

 
, and IL-6 mRNA
transcripts. A representative experiment is shown in Fig. 1.
The first signs of induction were detectable a few hours
after serum injection, with a modest but detectable rise from
the baseline for all mRNAs at 6 h. TNF
 

 
 message increased
more substantially from 24 h onwards. IL-1 transcripts fol-
lowed roughly the same pattern, but with a sharper induc-
tion at 48 h and far more extensive induction, reaching
13,000-fold at maximum. IL-6 showed a delay, with a max-
imum by 72 h followed by a decline at 144 h that was re-
producibly observed in several experiments. These results
are consistent with an early appearance of inflammatory cy-
tokine transcripts (from cell recruitment, or from true in-
duction of gene expression, or both), and a secondary, far
more extensive, induction. The induction of IL-1 appears
significantly more extensive than that of TNF-
 

 
.
 
No Role for IL-6.
 
The induction of arthritis by K/BxN
serum transfer does not require any contribution from T or
B cells (6). Thus, one can readily evaluate the role of in-
flammatory cytokines purely on the effector phase of the
disease, unencumbered by their influences on the immuno-
logical induction phase. Such complications may have
clouded results from collagen-induced arthritis (CIA) and
antigen-induced arthritis models, where the known pleio-
tropic effects of such cytokines on the structure or respon-
siveness of the immune system complicate data interpreta-
tion. The K/BxN serum transfer system is applicable to a
number of mouse strains (9), allowing one to investigate
the effects of diverse natural and engineered mutations.
This strategy was applied here, focusing on the contribu-
tions of IL-1, IL-6, and members of the TNF family, by
transferring K/BxN serum into homozygous knockout
mice lacking particular cytokines or cytokine receptors.
Mice of matched genetic composition, bred in the same
colony, were used as controls. In most cases, we preferred
not to rely on injected cytokine inhibitors, such as anticy-
tokine antibodies or soluble receptor molecules because
negative results with such reagents can be difficult to inter-
pret (sufficient dose or stability of the compound? com-
pleteness of the blockade?). This is particularly an issue in a
context as aggressive as that of K/BxN arthritis.
We first investigated the importance of IL-6, a
pleiotrophic cytokine expressed by a variety of cell types
during inflammatory processes (24). IL-6 has complex pro-
and antiinflammatory influences, with both local and sys-
temic effects. For example, it promotes immune responses
and plasma cell and macrophage differentiation (25), but
also induces acute phase proteins, IL-1 receptor antagonist
(26), and metalloproteinase inhibitors (27). Its role is vari-
able in different inflammatory models (28). There have
been conflicting reports of the requirement for IL-6 in an-
imal models of arthritis: some investigators describe re-
duced disease in IL-6–deficient mice or after antibody
blockade of its receptor (29, 30), whereas others report no
such effect (31).
IL-6–deficient mice on the C57Bl/6 background (14)
were transferred with serum from arthritic K/BxN mice,
and arthritis development was monitored as described pre-
viously (6). The representative experiment in Fig. 2 A dem-
onstrated a very similar arthritis course in IL-6–deficient
and control mice. The initial onset of symptoms was the
same, all distal joints were affected, and with a comparable
degree of inflammation (measured as ankle thickness).
These observations were confirmed by results from three
individual experiments tabulated in Fig. 2 B. Histological
examination of the ankle joints revealed the image of syno-
vitis and joint infiltration typical of K/BxN mice (synovial
thickening and infiltration, presence of neutrophils in the
articular cavity, pannus formation, and cartilage destruction;
Fig. 2 C; unpublished data). Furthermore, cartilage damage
and proteoglycan loss was evident on toluidine blue–stained
ankle sections from serum-injected mice at comparable lev-
els for IL-6–deficient and control mice (unpublished data).
These data are in agreement with those of van den Berg
and colleagues, who found little role for IL-6 in joint in-
flammation in CIA or zymosan-induced arthritis (31).
They contrast with other reports showing an effect of IL-6
blockade in the CIA model (29, 30). The explanation for
these discrepancies may lie in the positive impact of IL-6
on the immunological initiation phase of the CIA model:
less intense immune responses were made to the colla-
gen-II antigen in the absence of IL-6 function (29, 30).
Together, then, the data are consistent with the notion that
IL-6 does not play a major role in the inflammatory effec-
tor phase of arthritis.
 
An Essential Role for IL-1.
 
Although attempts at block-
ing the IL-1 pathway in RA patients in therapeutic trials
have not met with as much success as those interfering with
the activity of TNF
 

 
, there exists a substantial body of evi-
dence implicating this inflammatory cytokine in several
Figure 1. Kinetic of inflamma-
tory cytokine expression. Arthri-
tis was induced by injection of
K/BxN serum into naive
C57Bl/6 mice, and RNA was
prepared from ankle joint cavities
at various points thereafter.
mRNA encoding inflammatory
cytokines were quantitated by
real-time PCR using cyclophilin
mRNA as an internal standard.
The results are presented as rela-
tive expression of the individual
cytokine mRNAs standardized
against a reference sample of total
spleen RNA from a normal
mouse. This is a representative
experiment (of three), with two
mice pooled for each point.
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classic murine arthritis models, whether autoimmune in na-
ture or induced by local microbial particles (32–36); simi-
larly, high levels of IL-1 transcripts have been detected in
RA synovium (4, 37).
We tested the susceptibility to serum-transferred arthritis
of the IL-1R knockout strain (15), in which neither IL-1
 

 
nor IL-1
 

 
-mediated signals are possible. After K/BxN se-
rum transfer, essentially no clinical signs of disease were ob-
served in the IL-1R–deficient mice, except for a limited
swelling of the digits and a slight flutter in the ankle-thick-
ness curve (Fig. 3). To guard against possible influences of
genetic background variability, we repeated the initial
experiments performed in (B6 
 

 
 129)F2 mice in IL-IR–
deficient mice thoroughly backcrossed onto the B6
background (our standard fully susceptible background;
reference 11). Matched wild-type controls responded as
usual. Histologically, no signs of joint inflammation were
apparent in the four mice analyzed. Naturally, cartilage de-
struction and bone erosion were absent.
These clear-cut results indicate that, in this serum-trans-
fer model mediated by arthritogenic Igs, IL-1 plays a cen-
tral role, critically required for disease progression. We
have not been able to reproduce this effect by treatment
with blocking anti–IL-1R mAb (unpublished data), likely
because of the known difficulty to achieve complete block-
ade of IL-1 action with biomolecule inhibitors (for review
see reference 4) The central importance of IL-1 in the K/
BxN model is reminiscent of its requirement in CIA and
other murine arthritis models (32, 33, 35). It is also consis-
tent with the finding that intraarticular expression of IL-1
 

 
,
alone, is sufficient to induce full-blown arthritis (38).
 
TNF Family Influences.
 
Members of the TNF family
have received a great deal of attention in the context of
inflammatory arthritis. This has ranged from the initial
demonstration of TNF-
 

 
 expression in arthritic syn-
ovium, to establishing the efficacy of TNF-
 

 
-/TNFR-
blocking agents in animal models, to the successes of such
reagents in therapeutic intervention in human RA (1, 4,
39–42). Aberrant expression of TNF-
 

 
 is also sufficient to
induce arthritis in transgenic animals (43). These results
evoked models of arthritogenesis in which TNF-
 

 
 plays a
central and indispensable role (for review see 1). We
tested the efficacy of K/BxN serum transfer in animals
carrying knockout mutations of the genes encoding
TNF-
 

 
 or its close homologue, lymphotoxin (LT)-
 

 
(17–21). TNF-
 

 
 and LT-
 

 
 mediate their pleiotropic ef-
fects by binding to one of two known receptors, TNFR1
(p55) and TNFR2 (p75). 
We also investigated the effect of knockout mutations of
the genes encoding either or both of these molecules. The
data, summarized in Table I, allow several conclusions.
First, and most simply, LT-
 

 
 seemed not to be required for
the development of K/BxN serum-transferred arthritis.
LT-
 

 
–deficient mice responded normally on all counts, in
the kinetics and intensity of inflammation and in the ap-
pearance of histological lesions (proliferative synovitis, infil-
tration of the joint cavity by neutrophils, and formative of a
destructive pannus). 
Second, the absence of TNF-
 

 
 had a marked impact on
arthritogenesis. Many TNF-
 

 
–deficient mice developed no
disease whatsoever upon transfer of K/BxN serum, either
clinically or histologically (Table I). However, a number of
such animals did develop joint inflammation, overall in 9/
Figure 2. No requirement for IL-6 in arthritis induced by K/BxN se-
rum transfer. IL6-deficient and control mice (matched for gender/age and
genetic background) were injected with 150 l serum from arthritic
K/BxN animals on days 0 and 2. Arthritis was evaluated by measuring
clinical index and ankle thickening (Materials and Methods). (A) Data
from a representative experiment, with each curve representing an indi-
vidual mouse. (B) Tabulation of the results for 10 knockout mice and
age/gender matched controls; MaxAT, maximum increase in ankle thick-
ness in millimeters. MaxCI, maximum clinical index, sum of scores on
each limb (for each limb: 0, no disease; 0.5, mild swelling of paw or of
just a few digits; 1, clear joint inflammation in ankle or wrists); maximum
score 	 4. The histological score sums scores from knee, ankle, and tarsal
joints (1, minimum synovial hyperplasia; 2, limited inflammatory infiltra-
tion; 3, massive infiltration; 4, massive infiltration with cartilage and bone
destruction); maximum score 	 12.
Figure 3. Essential role of IL-1 ILIR–deficient and control mice
(matched for gender/age and genetic background) were injected with 150
l serum from arthritic K/BxN animals on days 0 and 2. Arthritis was
evaluated by measuring clinical index and ankle thickening as in Fig. 2.
(A) Data from a representative experiment in B6 recipients, with each
curve representing an individual mouse. (B) Tabulation of the results for
eight knockout mice and age/gender matched controls on either the stan-
dard (B6  129)F2 background or on an inbred B6 background. Scoring
as described for Fig. 2; the star denotes a transient inflammation in the
digits of one mouse.
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23 examined over the course of this study. This finding is
illustrated for representative cohorts in Fig. 4. The presence
of responder TNF
 

 
/
 

 
 mice was not restricted to one or
two experimental groups, but was observed in a number of
independent experiments. In contrast, a certain degree of
clustering was observed, some experimental groups show-
ing a high incidence of arthritis development (see below).
When disease did develop, the time of onset was quite
variable, usually delayed by several days relative to wild-
type controls, and the degree of inflammation always re-
mained below the maximum attainable. Histological analy-
sis also revealed significant signs of inflammation in those
mice with clinically detectable arthritis.
Third, joint inflammation developed normally in both
the TNFR1- and TNFR2-deficient mice, as well as in
TNFR1/TNFR2 double–deficient animals (Table I; the
genotypes of the mice were reconfirmed at the end of the
experiment). Clinical and histological parameters were es-
sentially indistinguishable from normal controls. This ob-
servation was quite unexpected, as TNFR1 and TNFR2
are the only known receptors for TNF-, with no reported
indication of another possible receptor in spite of the broad
attention that TNF- has received (44). As both the cyto-
kine and cytokine receptor mutations were on a susceptible
(B6  129) F2 background, one would have expected that
they have the same phenotype in both deficient strains.
These conflicting results prompted us to question the ef-
fect of the TNF- mutation: was the poor responsiveness
in TNF-–deficient mice truly due to the absence of the
cytokine, or instead to some independent factor (a linked
gene effect, quite plausible given the genomic localization
of the TNF locus; an independent mutation; protective
genes segregating by chance, etc.)? If the former were true,
it should be possible to complement the deficiency by
TNF- replacement, e.g., by triggering TNFR1 with an
agonistic mAb. To test this prediction, we injected cohorts
of TNF-deficient mice with K/BxN serum, selected
those mice that remained free of arthritis after 7 d, and ad-
ministered the agonistic anti-TNFR1 Ab 55R-593 (45). As
shown in Fig. 5, the Ab had a marked effect, provoking ar-
thritis in all the TNF-–deficient mice that had previously
received K/BxN serum. No arthritis was observed when
55R-593 was injected without serum pretreatment (un-
published data). Several control mAbs were used in parallel
to rule out trivial explanations for this observation: an iso-
type-matched control Ab, anti-TNFR1 mAbs with block-
ing or antagonist activity (55R-170, 55R-286). None of
these reagents induced arthritis (Fig. 5 B), at least not be-
yond the minority of TNF-–deficient mice one might
expect to eventually progress spontaneously to arthritis on
the basis of the results presented in Fig. 4. Thus, results
from these experiments confirmed that TNF- is indeed
the element missing in TNF-–deficient mice that is re-
quired for robust development of arthritis.
Table I. Arthritis Incidence in Mice Deficient in TNF and TNFR Families
Strain Arthritis Days of onset Max CI
TNFR1 
/
 8/8 4, 2, 2, 1, 1, 2, 2 3, 4, 4, 4, 4, 4, 4, 3
(B6) / 8/8 4, 2, 2, 3, 2, 3, 5, 2 4, 3, 4, 3, 4, 3.5, 2.5, 2.5
TNFR2 
/
 8/8 4, 2, 2, 1, 1, 1, 2, 2 3, 4, 4, 4, 4, 4, 4, 3
(B6) / 8/8 1, 4, 1, 1, 1, 1, 1, 2 4, 4, 4, 4, 4, 4, 4, 3.5
TNFR1/2 
/
 6/6 2, 2, 1, 4, 2, 2 4, 4, 4, 1.5, 3.5, 3
(B6x129F2) / 6/6 3, 7, 2, 2, 2, 2 2.5, 0.5,4, 4, 4, 4
Lt 
/
 8/8 2, 2, 2, 2, 2, 1, 4, 2 4, 4, 4, 4, 4, 2, 4, 3
(B6x129F2) / 8/8 2, 2, 5, 3, 2, 2, 2, 2 2, 2, 3, 3, 4, 4, 4, 4
TNF 
/
 9/9 2, 2, 2, 3, 5, 4, 2, 3, 3 2.5, 4, 4, 4, 2, 4, 4, 2.5, 3.5
(B6x129F2) / 4/14 -, -, -, -, 8, 19, -, -, - 0, 0, 0, 0, 1.5, 1, 0, 0, 0
2, 5, -, -, -, 1 4, 1.5, 0.5, 0.5, 0.5
Figure 4. Variability of arthritis in TNF-deficient mice. TNF-defi-
cient (left) and control mice (right; matched for gender/age and genetic
background) were injected with 150 l serum from arthritic K/BxN ani-
mals on days 0 and 2. Arthritis was evaluated by measuring ankle thicken-
ing as in Fig. 2. The data are pooled from six different experiments. All
mice originated from the Jackson Laboratory.
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Further experiments were performed to address the
cause of the variable effect of the TNF- deficiency. It
could be explained by genetic, epigenetic, or environmen-
tal variation controlling the activity of TNF-–indepen-
dent pathways; stochastic threshold effects could also be in-
volved, arthritogenesis requiring a certain degree of local
inflammatory insult, only seldom reached in the absence of
TNF-. As the knockout mutation was carried on a mixed
(129xB6) F2 background, we reasoned that modifier alleles
at other loci, able to complement the TNF deficiency,
might segregate randomly in the F2 knockout mice. To
test this hypothesis, several crosses were set up between
combinations of resistant or susceptible TNF-–deficient
mice. Should alleles at independent loci be segregating,
there should be heritable transmission of these traits to the
progeny. As shown in Fig. 6 A, this was not the case. A
cross between two resistant mice yielded a dominant pro-
portion of responder mice; the transmission of a recessive
susceptibility allele in this family would be very unlikely to
yield such a pattern (P  0.001). Thus, the variability does
not stem from Mendelian genetic elements. Epigenetic
variation could perhaps account for these results. However,
we observed a clear correlation between the origin and life
history of the mice and their responses to K/BxN serum
(Fig. 6 B). Those mice bred at the Jackson Laboratory and
shipped to Boston 7–15 d before challenge showed mainly
a resistant phenotype, whereas those bred in Boston and
tested there were mainly susceptible (P  0.003). In both
cases, the barrier facilities have SPF status, free of major
mouse pathogens, but minor bacterial flora varies. Thus,
the segregation of responses is more consistent with an en-
vironmental explanation than with an epigenetic one.
Together, these experiments point to a distinct involve-
ment of TNF- in Ab-induced arthritis, but one that is not
absolutely essential. This conclusion differs from that
reached by Kyburz et al. (13), who found no effect of anti-
TNF- therapy in arthritis development in straight K/BxN
transgenic mice. We have also made similar observations,
injecting several different anti-TNF- reagents into young
K/BxN mice (unpublished data). However, we interpret
these negative results with caution because of the very ag-
gressive nature of the disease that develops in the transgenic
mice and uncertainties concerning the efficiency of Ab-medi-
ated blockade. On the other hand, the present results do
concur with reports of robust development of CIA in TNF-
–deficient mice (46). Although it is conceivable that the
cytokine network adapts somewhat in TNF-–deficient an-
imals, other compensatory cytokines being more active than
usual, the results do show that TNF- is not the indispens-
able cytokine for the development of Ab-induced arthritis.
The significant mouse-to-mouse variability we observed
with TNF-–deficient animals is, in a sense, reminiscent of
the variability in the response of RA patients to TNF-/
TNFR blockade (1). The results of Fig. 6 make it perhaps
more plausible that environmental effects are at play, the
degree of TNF- involvement being dependent on the
general inflammatory state of the individual. It should be
worthwhile trying to pinpoint what these influences might
be, in both mice and humans, and the present system does
provide a handle.
There are several potential interpretations for the strong
arthritis that develops in TNFR1/2-deficient mice. The
most straightforward is that other receptors can compensate
and mediate TNF- signals. Although the existence of such
a receptor has not been reported to date, the breadth of the
TNFR family makes it quite possible that other receptors
will be found to bind TNF-. Whether these are indeed
the primary receptors mediating arthritis, or whether they
only come into play when the primary TNFR1/2 receptors
are absent, will need to be explored. Alternatively, one
might propose that TNF-–independent arthritis pathways
are particularly active when TNFR1/2 are missing, perhaps
by commandeering downstream signal transduction adap-
Figure 5. Triggering the TNF receptor complements TNF defi-
ciency. TNF-deficient mice were injected with 150 l serum from ar-
thritic K/BxN animals on days 0 and 2. Animals not presenting any signs
of disease by day 7 were injected at days 7, 11, and 15 with anti-TNFR1
mAb 55R-293, which has significant agonist activity (A) or with control
mAbs (B). These controls included anti-TNFR1 reagents devoid of ago-
nist activity or an irrelevant mAb. (C) Anti-TNFR mAbs were injected
without K/BxN serum. Arthritis was evaluated by measuring ankle thick-
ening as above. The data are pooled from four different experiments. All
mice originated from the Jackson Laboratory.
Figure 6. Environmental, not genetic, influences on TNF-indepen-
dent arthritis. (A) TNF-deficient mice from the Jackson Laboratory
were tested by transfer of K/BxN serum, and animals of different pheno-
types were crossed (white symbols, resistant mice; black symbols, suscep-
tible mice, where resistance and susceptibility are defined as the presence
of clear arthritis [grade  1]) in the first 10 d after serum transfer. Their
progeny was similarly tested when 4–5 wk old. (B) A compilation of re-
sults of challenge of TNF-deficient mice with K/BxN serum, either
from mice purchased from the Jackson Laboratory or bred in our Boston
colony; 2, P 	 0.003.
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tors. For example, the absence of TNFR1 might free
TRADD, FADD, or TRAF molecules for more efficient
interaction with other receptors.
Bone Destruction and Formation. There is some debate
about the role of inflammatory cytokines in promoting fo-
cal bone erosion in the course of arthritic diseases. Osteo-
clasts are essential to the process, and essentially no focal
destruction of the bone occurs in their absence. Resistance
to bone erosion was previously demonstrated in mice defi-
cient in the TNF family member receptor activator of NF-
KB ligand (RANKL) that had received K/BxN serum, as
in the CIA model after blockade of RANKL by osteopro-
tegerin treatment (23, 47). This finding is consistent with
the fact that RANK/RANKL axis is required for the gen-
eration of osteoclasts and also plays a role in their activation
(for review see reference 48). In contrast, it is also possible
that other inflammatory cytokines play a role. IL-1 can
activate osteoclasts, and promotes bone resorption in vitro
(49, 50). TNF promotes osteoclast differentiation in the
presence of RANKL (51, 52), and there are indications that
TNF/TNFR blockade can retard bone destruction in RA
patients, even when the effect on the inflammatory com-
ponent is limited (53). Thus, we asked whether bone de-
struction could be seen in the absence of these cytokines.
As described previously, obvious instances of focal bone
destruction were seen in normal mice injected with K/
BxN serum; similar images were also observed in LT-
deficient mice (Fig. 7, A and B). For TNF-, we focused
in particular on those mice that showed significant joint in-
flammation. In these instances, clear evidence of focal bone
destruction was also observed (Fig. 7 C). Although impos-
sible to truly quantitate, given the variability of inflamma-
tion in the TNF-deficient animals, the extent of the erosive
lesions in the absence of TNF- was largely on par with
the extent of inflammation.
We could not draw any conclusion on the role of IL-1 in
bone destruction, as the upstream inflammatory phase did
not develop in its absence. However, our results are not
consistent with the view that TNF- plays an obligate role
in promoting bone destruction: synovitis and joint inflam-
mation could still lead to extensive destruction in its absence.
Synthesis: Intersection of IL-1 and TNF Pathways. There
has been quite some debate as to the relative roles and im-
portance of IL-1 and TNF- in arthritogenesis. In animal
models where the function of these cytokines has been
tested, their importance varies somewhat with the disease-
eliciting agent, although IL-1 may play a dominant role in
the cartilage and bone destruction that ultimately ensues
(for review see reference 4). For Ab-mediated arthritis that
the K/BxN disease may typify, our results point to a more
crucial function for IL-1. These roles, and the slightly dif-
ferent kinetics of induction of cytokine transcription in the
joint during arthritis initiation, are consistent with a model
in which the point of action of TNF- would be upstream
of that of IL-1 (1). TNF-–independent pathways, perhaps
relying on other members of the TNF family, may also
trigger IL-1 independently. This view is consistent with
the importance of TNF- in promoting IL-1 production
by synoviocytes from RA patients (54), or with the fact
that IL-1 blockade prevents the arthritis induced by trans-
gene-encoded TNF- misexpression (34). It should also be
pointed out that the experiments shown in Fig. 1 only de-
tect transcriptionally induced TNF- production. How-
ever, it is likely that even earlier release of TNF- occurs
in the first minutes or hours of the disease, released from
intracellular stores of synoviocytes or mast cells upon trig-
gering by C5a or FcRIII. These molecules constitute two
essential links between the anti-GPI Abs and the inflam-
matory manifestations of K/BxN arthritis (11), and both
pathways are known to precipitate rapid TNF- release.
The relevance of the Ab-mediated arthritis model that
K/BxN mice present to human arthritic diseases had been
questioned, in part, because it does not fit well with the
paradigm in which autoreactive T cells within the joint
provoke local TNF- release, a model bolstered by the
Figure 7. Bone destruction in control and KO mice. Bone erosion was
assessed in hematoxylin and eosin–stained ankle sections from TNF-
and LT-deficient mice and control mice after transfer of K/BxN serum.
(A) Control mouse, full inflammation and areas of focal bone destruction
(arrows). (B) Arthritic LT-deficient mouse with inflammation and focal
bone erosion. (C) TNF-deficient mouse with clinical manifestations,
showing inflammation and focal bone erosion. (D) TNF-deficient
mouse with no clinically detectable symptoms, showing minimal in-
flammation (matched with A).
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successes of anti–TNF- therapy. The present results show
that arthritis induced by Ab complexes in the joint also end
up with the production of TNF- and IL-1, and is highly
dependent on these cytokines.
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